产品描述

EIDD-2801 is an isopropylester prodrug of the ribonucleoside analog N 4-hydroxycytidine (EIDD-1931) that has shown broad influenza virus and multiple coronaviruses activity.

靶点活性

SARS-CoV

体内活性

EIDD-2801 was orally bioavailable in ferrets and nonhuman primates. Therapeutic oral dosing of influenza virus-infected ferrets reduced group pandemic 1 and group 2 seasonal influenza A shed virus load by multiple orders of magnitude and alleviated fever, airway epithelium histopathology, and inflammation, whereas postexposure prophylactic dosing was sterilizing[1].

别名

化合物EIDD-2801 , Molnupiravir，莫纳皮拉韦

纯度

98%

分子量

329.31

分子式

C13H19N3O7

CAS No.

2349386-89-4

存储

Powder: -20°C for 3 years

In solvent: -80°C for 2 years

溶解度

DMSO: 100 mg/mL (303.67 mM), Need ultrasonic

DMSO: 10 mM

( < 1 mg/ml refers to the product slightly soluble or insoluble )

参考文献

1. Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: eaax5866.

2. Mart Toots , Jeong-Joong Yoon , Michael Hart ,et al.Quantitative Efficacy Paradigms of the Influenza Clinical Drug Candidate EIDD-2801 in the Ferret Model.ransl Res. 2020 Apr;218:16-28.

3. Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883.

Note

For research use only.